Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) just unveiled an announcement.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced that its new drug application for A400/EP0031, a RET kinase inhibitor, has been accepted for review by China’s National Medical Products Administration. This drug targets RET-fusion positive non-small cell lung cancer and has shown promising results in Phase 2 studies, demonstrating efficacy and a manageable safety profile. The acceptance of this application marks a significant step in the company’s efforts to advance cancer treatment options and could enhance its positioning in the oncology market.
The most recent analyst rating on (HK:6990) stock is a Hold with a HK$434.36 price target. To see the full list of analyst forecasts on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock, see the HK:6990 Stock Forecast page.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a biopharmaceutical company based in China, focusing on the development of innovative drugs for cancer treatment. The company specializes in small molecule drugs, with a particular emphasis on RET kinase inhibitors for treating various cancers, including non-small cell lung cancer (NSCLC) and medullary thyroid cancer (MTC).
Average Trading Volume: 822,127
Technical Sentiment Signal: Buy
Current Market Cap: HK$118.8B
Find detailed analytics on 6990 stock on TipRanks’ Stock Analysis page.